As of November 30, 2025, the 10‑year window for this prediction (through roughly mid‑2031) has not expired, so it is too early to say definitively whether it will prove right or wrong.

Evidence on the technology trajectory:

• MIT researchers have built a tabletop "mobile vaccine printer" that produces microneedle‑patch vaccines and is explicitly framed as enabling on‑demand, decentralized vaccine production; it has been demonstrated in mice but is still a research prototype, not a widely deployed commercial product.【0search3】
• CureVac has developed "The RNA Printer," a downsized, integrated and automated GMP‑grade mRNA manufacturing system intended as a mobile, modular facility for RNA vaccines and therapeutics. CureVac created a dedicated subsidiary (CureVac RNA Printer GmbH) in 2022 to advance it and has obtained initial manufacturing licenses in Germany, but current public information describes it as an in‑house/partner platform in regulatory review and development, not yet a globally deployed fleet of printers.【2search0】【2search2】
• BioNTech’s modular "BioNTainer" units—containerized mRNA manufacturing facilities shipped to Rwanda and planned for other African countries—are another step toward decentralized mRNA production, but they are large container factories (two modules covering ~800 m²) rather than the kind of small, bioreactor "printer" Friedberg described, and they are only in a few locations so far.【1search0】【1search6】

Evidence on deployment scale vs. the claim:

• None of the above efforts are yet described in 2025 sources as small vaccine printers that are broadly "deployed around the world" in routine use. Instead, they are in R&D, pilot, or early facility‑buildout stages.【0search3】【2search1】【1search1】
• However, multiple companies (CureVac, BioNTech, academic/industry collaborations at MIT and others) are clearly pursuing exactly the kind of digitally programmable, small‑footprint or modular vaccine manufacturing systems Friedberg envisioned.【0search3】【2search3】

Because (1) the forecast horizon still runs for nearly six more years, and (2) the key condition—widespread global deployment of such vaccine printers—is not yet met but also not ruled out, the correct status for this prediction as of late 2025 is **"inconclusive (too early)."